Live
- Tata Motors begins delivery of 148 EVs to BMTC
- Vanya Steels to invest Rs 100 cr in 10 MW green power plant
- Charges filed in Parashurama statue case
- Native chicken thefts leave Chikkaballapur farmers sleepless
- Moodabidri lecturers held for rape in Bengaluru
- Legendary film actress Saroja Devi laid to rest with full state honours
- Tourists voice anger: Chamarajanagara’s much-awaited elephant camp yet to open
- Twins Surabhi and Samriddhi say competing separately in ‘Chhoriyan Chali Gaon’ will be a new challenge
- This is what Sonam Kapoor has to say on ‘desification’ of Wimbledon
- Pakistan's Malfunctioning Drones Found Intact During Operation Sindoor, Reveals India's Defence Chief
Zydus gets USFDA nod to market generic medication
Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
New Delhi: Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Methylene Blue injection in strengths of 10mg/2ml and 50mg/5ml, the drug firm said in a statement. Zydus' product is the generic version of ProvayBlue injection.
The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation, the company stated. From a hospital perspective, a vial presentation is an affordable option with significant benefits and advantages, it added.
Methylene Blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. As per IQVIA MAT data, Methylene Blue injection (10mg/2ml and 50mg/5ml) had an annual sale of around USD 73.4 million in the US.
